Editorials Bringing Vioxx back to market BMJ 2018; 360 doi: https://doi.org/10.1136/bmj.k242 (Published 25 January 2018) Cite this as: BMJ 2018;360:k242 Article Related content Metrics Responses Peer review Related articles News Merck used ghostwriters and selective data in Vioxx publications, JAMA says Published: 17 April 2008; BMJ 336 doi:10.1136/bmj.39553.344965.DB Feature What have we learnt from Vioxx? Published: 18 January 2007; BMJ 334 doi:10.1136/bmj.39024.487720.68 BMJ opinionBringing Vioxx back to life See more Charles Derek Holdsworth BMJ January 26, 2023, 380 p189; DOI: https://doi.org/10.1136/bmj.p189 Geoffrey Brigden BMJ January 26, 2023, 380 p183; DOI: https://doi.org/10.1136/bmj.p183 Maurice Michael Hegarty BMJ January 26, 2023, 380 p188; DOI: https://doi.org/10.1136/bmj.p188 Henry Halliday BMJ January 26, 2023, 380 p186; DOI: https://doi.org/10.1136/bmj.p186 Anne Sterndale-Bennett BMJ January 26, 2023, 380 p181; DOI: https://doi.org/10.1136/bmj.p181
